CTI BioPharma Profit Margin

The latest profit margin for CTIC is -102.43% as of March 2023. That compares with -5133.64% in the prior-year period — up 98.0% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside CTI BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, CTIC's profit margin moved from -5133.64% to -102.43% — a 98.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CTI BioPharma's valuation or profitability profile.

Against Healthcare companies, CTIC currently prints -102.43% for profit margin, while the sector average sits near 10.58%. That is roughly 1068.1% below the sector mean. Large gaps often invite a closer look at CTI BioPharma's growth, margins, and balance sheet.

Profit Margin shows how effectively CTI BioPharma converts resources into returns. At -102.43%, CTIC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -5133.64% in the prior-year period — up 98.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CTIC's profit margin (-102.43%), review year-over-year change from -5133.64%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.